A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

•First line therapy in metastatic uterine leiomyosarcoma is gemcitabine and docetaxel.•There is no standard second line therapy for metastatic uterine leiomyosarcoma.•Ixabepilone is not active in second line for disease previously treated with a taxane.